Sito Bio(SZ:300583)2022-08-29 16:00Financial Performance - The company's operating revenue for the first half of 2022 was CNY 636,242,960.65, representing a 2.03% increase compared to CNY 623,607,764.69 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was CNY 32,339,106.58, a significant increase of 70.17% from CNY 19,003,606.57 in the previous year[23]. - The net profit after deducting non-recurring gains and losses reached CNY 30,750,102.42, marking a 376.30% increase compared to CNY 6,456,016.31 in the same period last year[23]. - Cash flow from operating activities surged to CNY 182,721,185.87, a remarkable increase of 2,024.10% from CNY 8,602,296.58 in the previous year[24]. - Basic earnings per share rose to CNY 0.30, up 66.67% from CNY 0.18 in the same period last year[24]. - Total assets at the end of the reporting period were CNY 3,219,475,133.82, an increase of 8.41% from CNY 2,969,699,298.75 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company were CNY 1,712,375,060.99, reflecting a 1.76% increase from CNY 1,682,729,774.58 at the end of the previous year[24]. - The weighted average return on net assets was 1.90%, an increase of 0.75% compared to 1.15% in the previous year[24]. Investment and Projects - The company has invested ¥35,998.80 million in the project for an annual production of 700 tons of 9-hydroxyandrostenedione, and ¥23,475.55 million in the steroid intermediates and raw materials project[78]. - The company has adjusted the investment plan, terminating the construction of the 120 tons of 4-ene and 180 tons of dihydroxyprogesterone production lines, focusing on the 700 tons of 9-hydroxyandrostenedione production line[79]. - The company has allocated ¥27,000.00 million of repurposed funds to a new project for steroid intermediates and raw materials, with a total investment of ¥45,091.00 million[79]. - The company has used ¥11,460.00 million of repurposed funds to acquire 100% equity of Runxin Thermal Power[80]. - The annual net profit expected from the "700 tons of 9-hydroxyandrostenedione, 120 tons of 4-androstenedione, and 180 tons of hydroxyprogesterone project" was originally estimated at CNY 472.17 million, but after adjustments, the average annual net profit is now projected to be CNY 159.39 million[84]. - The "steroid intermediates and raw materials project" has completed the construction of three workshops, two warehouses, and a control center, but is still pending some equipment installation due to pandemic-related delays[84]. - The completion deadline for the "steroid intermediates and raw materials project" has been extended to May 1, 2023, with partial construction completed as of June 30, 2022[84]. Subsidiaries and Equity - The subsidiary Disen Bio reported a net profit of CNY 19.85 million, contributing significantly to the company's overall performance[95]. - The subsidiary Sry Pharmaceutical achieved a net profit of CNY 8.99 million, reflecting its role in the company's profitability[95]. - The company holds 100% equity in Disen Bio and 85% in Sry Pharmaceutical, indicating strong control over its key subsidiaries[97][98]. Environmental and Social Responsibility - The company is committed to environmental protection and has invested in reducing pollution during production processes[108]. - The company emphasizes its commitment to environmental protection and sustainable development, focusing on resource efficiency and waste management[148]. - The company actively engages in social responsibility initiatives, contributing to community management and public welfare[147]. - Environmental monitoring is conducted regularly by third parties, with results publicly disclosed[143]. - The company has established an emergency response plan for environmental incidents, which has been filed with local authorities[142]. Share Capital and Stock Management - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company completed the cancellation of 330,500 restricted stocks due to unmet performance targets, reducing the total share capital from 107,252,567 shares to 106,922,067 shares[22]. - The company has implemented a stock incentive plan to enhance the responsibility and mission of its management team[116]. - The stock incentive plan was approved in 2017, granting 1.322 million shares to 47 incentive targets[118]. - The company completed a wastewater treatment facility with a capacity of 4,000 m³/d in June 2016 and another with a capacity of 3,600 m³/d in February 2021[133]. Financial Management and Compliance - The company has not engaged in any entrusted financial management, derivative investments, or entrusted loans during the reporting period[90][91][92]. - The company has not sold any major assets during the reporting period, maintaining its asset base[93]. - The company has maintained transparency in information disclosure, adhering to legal and regulatory requirements[149]. - The company borrowed a total of 9,000,000 RMB from its controlling shareholder, with an interest rate of 7.00%, resulting in an interest expense of 132.42 million RMB for the period[165]. - The financial report for the first half of 2022 was not audited[195].